280 related articles for article (PubMed ID: 35190830)
1. Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice.
Tsuruta A; Shiiba Y; Matsunaga N; Fujimoto M; Yoshida Y; Koyanagi S; Ohdo S
Mol Cancer Res; 2022 Jun; 20(6):972-982. PubMed ID: 35190830
[TBL] [Abstract][Full Text] [Related]
2. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.
Pu Y; Ji Q
Front Immunol; 2022; 13():874589. PubMed ID: 35592338
[TBL] [Abstract][Full Text] [Related]
4. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
5. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
7. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C
Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566
[TBL] [Abstract][Full Text] [Related]
8. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8
Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K
Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728
[No Abstract] [Full Text] [Related]
9. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
[TBL] [Abstract][Full Text] [Related]
10. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
Hartley GP; Chow L; Ammons DT; Wheat WH; Dow SW
Cancer Immunol Res; 2018 Oct; 6(10):1260-1273. PubMed ID: 30012633
[TBL] [Abstract][Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
12. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
13. Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy.
Li W; Wu F; Zhao S; Shi P; Wang S; Cui D
Cytokine Growth Factor Rev; 2022 Oct; 67():49-57. PubMed ID: 35871139
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.
Petty AJ; Dai R; Lapalombella R; Baiocchi RA; Benson DM; Li Z; Huang X; Yang Y
JCI Insight; 2021 Mar; 6(6):. PubMed ID: 33749663
[TBL] [Abstract][Full Text] [Related]
15. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers.
Zhang H; Liu L; Liu J; Dang P; Hu S; Yuan W; Sun Z; Liu Y; Wang C
Mol Cancer; 2023 Mar; 22(1):58. PubMed ID: 36941614
[TBL] [Abstract][Full Text] [Related]
16. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
18. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
Taube JM; Young GD; McMiller TL; Chen S; Salas JT; Pritchard TS; Xu H; Meeker AK; Fan J; Cheadle C; Berger AE; Pardoll DM; Topalian SL
Clin Cancer Res; 2015 Sep; 21(17):3969-76. PubMed ID: 25944800
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
Hang Q; Ying H; Cheng G; Yang S; Jin J; Chen Y; Chen Q; Jiang Y; Zhao Q; Fang M; Chen M; Lai X
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):837-844. PubMed ID: 33070512
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer.
Wang C; Xu YH; Xu HZ; Li K; Zhang Q; Shi L; Zhao L; Chen X
J Nanobiotechnology; 2023 Dec; 21(1):476. PubMed ID: 38082443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
